Main pageCompanyTechnologyPublicationsPatentsPartneringContact

Patents

We have a global IP portfolio consisting of patents or patent applications in nine patent families. In seven of these families we have patents granted in at least one territory. Present patent terms are between 2022 and 2029. We believe however that the patents will give a full protection until at least 2030 to 2037, as competing applications for marketing authorization likely will require a full dossier. We will continue to actively reinforce our patent position based on key findings in research and technology development.

SentoClone International is the owner of all patent rights outside China whereas Jiangsu Sinorda owns the patents within the People´s Republic of China.

Patent family 1: Cancer immunotherapy (EP 02022787.2)

Granted in Europe (2007), Australia (2008), New Zealand (2008), pending in other territories.

Patent family 2: Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer (PA 2005 01810, US 60/752,828)

Granted in Europe (2010), Mexico (2010), Australia (2011), New Zealand (2011), Singapore (2011), China (2011), USA (2012), pending in other territories.

Patent family 3: Method for treating disseminated cancer (PA 2005 01808, US 60/752,844)

Granted in Australia (2011), Singapore (2011), South Africa (2011), USA (2012), Canada (2012), Europe (2013), Japan (2013), pending in other territories.

Patent family 4: Method for treating urinary bladder cancer (PA 2005 01811, US 60/753,082)

Granted in USA (2012).

Patent family 5: Method for treating colon cancer (PA 2005 01812, US 60/752,829)

Granted in USA (2011).

Patent family 6: Method for treating malignant melanoma (PA 2005 01809, US 60/752,843)

Granted in Australia (2011), USA (2012).

Patent family 7: Multiplex detection of tumour cells using a panel of agents binding to extra cellular markers (US 60/903,986)

Granted in Russia (2013), pending in other territories.

Patent family 8: Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types. (US 12/147,752)

Granted in USA (2011) .

Patent family 9: Composition with VEGF inhibitor.

Pending.